Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
暂无分享,去创建一个
Gregg W Stone | G. Stone | D. Kereiakes | D. Cutlip | C. Simonton | R. Applegate | P. Sood | Dean J Kereiakes | Donald E Cutlip | Poornima Sood | Ali Rizvi | William Newman | Charles A Simonton | Krishnankutty Sudhir | A. Rizvi | W. Newman | James T. Maddux | Louis A Cannon | Robert J Applegate | K. Sudhir | James T Maddux | L. Cannon
[1] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[2] G. Stone,et al. Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial , 2009, Circulation.
[3] P. Smits,et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). , 2011, Journal of the American College of Cardiology.
[4] J. Habbema,et al. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? , 2006, American heart journal.
[5] P. Serruys,et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. , 2009, Circulation. Cardiovascular interventions.
[6] E. Hannan,et al. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies , 2009, Circulation.
[7] Stephen J. Williams,et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. , 2000, Cancer research.
[8] G. Stone,et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. , 2009, American heart journal.
[9] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[10] P. Ročić. Differential phosphoinositide 3-kinase signaling: implications for PTCA? , 2009, American journal of physiology. Heart and circulatory physiology.
[11] Eric L Eisenstein,et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. , 2009, Journal of the American College of Cardiology.